Why this is here
Most accounts of healthcare cost do one of two things. They overwhelm you with a number so large it feels like weather — something that happens to you, not something you can act on. Or they reduce people to line items, treating a patient as a cost to be managed down. This section refuses both.
We present these costs because they are not abstract and they are not elsewhere. They land in your body, your household, and your work. But there is a harder problem underneath them, and it is the actual reason this section exists.
The question this section actually asks
Everyone already knows healthcare is expensive. The figures in these primers are not secret and never have been. They are published annually by the federal government, analyzed by every research institution in the country, and cited in every campaign. Nobody is waiting to be informed.
Vermont knew them when it passed the first state universal care law in 2011 — and abandoned it three years later, before covering a single person, even though all three studies projected it would save money. Colorado knew them when it put a member-owned cooperative on the ballot in 2016 and watched it lose by fifty-eight points. California knew them when its Senate passed a plan analysts said would save $37 billion, and the Assembly shelved it. Britain knew them, made the turn decades ago, and then spent billions on a programme its own analysis judged not worth the money.
So the question this section actually asks is not how much does health care cost.
It is: why, when everyone knows, does nothing turn?
The answer is not in any of the numbers that follow. It is in what those numbers cannot see — and bringing light into that space is what this section exists to do.
Think of it as a dark room. The costs we know how to count are the objects near the door, lit well enough to inventory: the hospital bill, the premium, the prescription. Everything else sits in the dark. What a condition quietly takes from a person's capacity. What a relationship with a care team actually produces. What a life restored is worth to a household, an employer, a community. None of it is absent. All of it is uncounted — and what is uncounted is absent from every decision anyone makes.
Shed light into that room, and the counting can finally be done honestly: cost weighed against what care produces, rather than cost weighed against nothing at all. That is the work of this section, and it is why the primers that follow do not stop at the number.
Costs matter. They exist for reasons that can be named. And they can be improved — not by spending less on people, but by caring for them better. When care restores a person's capacity to live and work and participate, cost falls as a consequence. Human capacity is the point. Lower cost is what follows.
That is the advocacy of this section. And here is its problem, which is the problem of every attempt named above: nobody is counting capacity. We can measure to the dollar what a disease costs. We have no working measure of what a relationship with a care team produces. So every proposal to build better care arrives at the table as a visible, immediate, enormous cost — weighed against a benefit no one has ever quantified. The cost wins. It always wins.
So we keep the person first. A condition left unaddressed does not, first of all, "run up cost." It impedes a life — and that impediment is what then ripples outward into family strain and workplace loss and, eventually, the national numbers. We read the cost backward to the human being at its origin, because that is where the solution lives too.
Disease is not the whole of capacity
One more thing belongs in this introduction, because it changes how every number in this section should be read.
Clinical care tends to treat disease as a hard and fast fact — objectively present, fixed in size, either there or not. In practice it is not that simple. A condition can persist, unchanged on every test, while a person's relationship to it shifts — and when that shifts, their capacity shifts with it. The disease is still there. What they can do with their life is different.
That distinction matters enormously here, because capacity is what all the money in this section is ultimately trying to buy.
The clearest evidence comes from the work of Ted Kaptchuk at Harvard, whose research program carries a telling name: the Program in Placebo Studies and the Therapeutic Encounter. In a 2010 trial, patients with irritable bowel syndrome were given pills in bottles labeled placebo, and told plainly that the pills were pharmacologically inert and contained no medication. No deception of any kind. Fifty-nine percent of them reported adequate symptom relief, against thirty-five percent of those given no treatment. Later work has found similar effects in chronic low back pain, cancer-related fatigue, migraine, and allergic rhinitis — and a subsequent trial found that open-label placebo performed about as well as concealed placebo.
The samples are modest, and this is emphatically not a claim that perception cures disease. It does not. But the finding points somewhere specific and important: if people improve while knowing there is no drug, then something other than the drug is doing work. Kaptchuk's own conclusion is that the active ingredient is the therapeutic encounter itself — the attention, the explanation, the ritual, the relationship.
Which means the perception of disease and pain is not a soft factor sitting politely beside the clinical picture. It is inside it. Perception influences capacity. Capacity influences recovery. And recovery is the thing all this money is trying to purchase.
If the relationship between a patient and a care team is itself an active clinical ingredient — and the evidence says it is — then a measurement system that counts drugs and procedures and never counts the relationship is not merely incomplete. It is blind to one of the things that actually works. Hold onto that. It is where this section ends up.
How this section is organized
The section builds an argument in four parts, and it is meant to be walked in order.
The Landscape — the macro view. Where the money comes from, where it goes, what is wasted, who profits, and how the United States compares to the rest of the world. It establishes the scale of the problem and ends by proving that a different outcome is achievable.
The Record — so people tried. Four attempts at the turn: Vermont, Colorado, California, and the United Kingdom. Four failures, in the same place, for the same reason. These are presented as cases, in the same format the Case Library uses for clinical failures — because the failure of a system and the failure of a patient's care turn out to rhyme.
The Reframe — why all four died, and what changes when the question changes. This is the spine of the section and the reason it exists.
The Disease Burden — a closer look at specific conditions that drive an outsized share of the cost, chosen because they are the conditions this framework is built to address. This is where the abstract becomes personal, and where the path forward is most concrete. It reads as a reference track; take whichever condition touches your life or your workforce.
How each page reads
The disease pages follow a consistent three-part shape, so that once you know the format, you can move through any of them quickly:
What the condition costs and what actually drives that cost — presented so the numbers mean something rather than simply alarm.
How that cost shows up in a real life — in your day and body, in your family and household, and in your business. Not someone else's problem, somewhere else.
An actionable path forward, built on the framework's arc of care, with concrete samples for individuals, families, and employers. Nobody should leave a page with only a number.
The arc of care, applied to cost
The third part of every page — the path toward a solution — is built on the same clinical arc that guides an individual patient's recovery elsewhere on this site. Applying it to cost is deliberate: the whole point of the arc is that it refuses to stop at the diagnosis. Here, the framework treats the cost problem itself the way it would treat a patient — not by managing the symptom, but by moving through recovery toward genuine, sustained capacity.
The arc has four movements. We name each in the framework's clinical terms first, then in the plain terms that make it actionable against a cost. From here on, whenever you see these stages, they mean the same four steps.
The movement runs from what you can do this week, at the top, to the structural answer at the bottom — and it scales. The early stages are where an individual acts; the middle is where an employer has leverage; the final movement is where the system itself changes, which is the model this whole site describes. Same arc, whether the patient is a person or a country.
Cost figures move every year, and they come from many methodologies that are not cleanly comparable. We source every figure, prefer original sources, and note what each number includes. Where an estimate is uncertain or a range, we say so. The goal is an honest picture you can act on — not the scariest possible total.
Where to start
If you have the time, walk it in order. Begin with the total and move through the landscape, then the record, then the reframe. The argument is cumulative, and the ending only lands if you have felt the weight of what comes before it.
If you are short on time and want the thesis, read the measurement problem and then the turn. Those two primers are the spine of this section, and everything else is the evidence that makes them necessary.
And if you came here because a specific condition touches your life or your workforce, go straight to it in the disease burden list. Those primers stand on their own and each ends with a concrete path forward.